Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9021964 | International Congress Series | 2005 | 5 Pages |
Abstract
Uterine artery embolisation (UAE) is a new treatment for heavy menstrual bleeding caused by uterine fibroids. The EMMY trial evaluates the safety and efficacy of UAE in a randomised comparison to hysterectomy. Patients were included when they had uterine fibroids and menorrhagia and were eligible for hysterectomy. The primary endpoint is the elimination of menorrhagia after a 1-year follow-up period. Secondary endpoints comprise: effect on complaints of pain and pressure, quality of life issues, uterine volume reduction, effect on ovarian function and cost-effectiveness. 177 Patients were randomly assigned (1:1) to either UAE (n=88) or hysterectomy (n=89). The results of this trial will be presented at a later stage. UAE is already being performed on a regular basis, without profound evidence: no good quality randomised controlled trials have been conducted. This trial is the first to evaluate the value of UAE in clinical practice with a control group. Whether UAE can replace hysterectomy as treatment of first choice depends on the balance of efficacy, costs and quality of life.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Molecular Biology
Authors
Wouter J.K. Hehenkamp, Nicole A. Volkers, Erwin Birnie, Jim A. Reekers, Willem M. Ankum,